Compare AIIR & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIIR | KARD |
|---|---|---|
| Founded | 1999 | 2023 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2025 | 2026 |
| Metric | AIIR | KARD |
|---|---|---|
| Price | $7.58 | $13.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $10.75 | ★ $39.50 |
| AVG Volume (30 Days) | 46.5K | ★ 571.5K |
| Earning Date | N/A | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.29 | $12.23 |
| 52 Week High | $8.97 | $27.00 |
| Indicator | AIIR | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 42.48 |
| Support Level | $6.62 | $12.23 |
| Resistance Level | $8.40 | $15.93 |
| Average True Range (ATR) | 0.49 | 1.11 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 36.21 | 30.46 |
AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.